Gyre Therapeutics (GYRE) 10-Q 11 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	CBIO
Entity Registrant Name	CATALYST BIOSCIENCES, INC.
Entity Central Index Key	1,124,105
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		4,260,561

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 14,533	$ 10,264
Short-term investments		6,800
Restricted cash	12,735	19,468
Accounts receivable	227	31
Prepaid and other current assets	1,041	958
Total current assets	28,536	37,521
Restricted cash, noncurrent	125	125
Property and equipment, net	399	444
Total assets	29,060	38,090
Current liabilities:
Accounts payable	899	837
Accrued compensation	645	596
Other accrued liabilities	730	805
Deferred revenue, current portion	259	283
Deferred rent, current portion	40	41
Redeemable convertible notes	12,651	19,403
Total current liabilities	15,224	21,965
Deferred revenue, noncurrent portion		47
Deferred rent, noncurrent portion		7
Total liabilities	15,224	22,019
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares and no shares authorized and outstanding at both March 31, 2017 and December 31, 2016
Common stock, $0.001 par value, 100,000,000 shares authorized; 1,000,036 and 801,756 shares issued and outstanding at March 31, 2017 and December 31, 2016	2	1
Additional paid-in capital	165,954	164,053
Accumulated other comprehensive income (loss)		(1)
Accumulated deficit	(152,120)	(147,982)
Total stockholders’ equity	13,836	16,071
Total liabilities and stockholders’ equity	$ 29,060	$ 38,090

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,000,036	801,756
Common stock, shares outstanding	1,000,036	801,756

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Contract revenue	$ 271	$ 109
Operating expenses:
Research and development	2,061	2,286
General and administrative	2,381	2,395
Total operating expenses	4,442	4,681
Loss from operations	(4,171)	(4,572)
Interest and other income, net	33	980
Net loss	$ (4,138)	$ (3,592)
Net loss per common share, basic and diluted	$ (4.57)	$ (4.71)
Shares used to compute net loss per common share, basic and diluted	906,048	762,007

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,138)	$ (3,592)
Other comprehensive income (loss):
Unrealized gain on available-for-sale securities	1	3
Total comprehensive loss	$ (4,137)	$ (3,589)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders Equity (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2016	$ 16,071	$ 1	$ 164,053	$ (1)	$ (147,982)
Balance (in shares) at Dec. 31, 2016		801,756
Stock-based compensation expense	120		120
Issuance of stock, value	1,782	$ 1	1,781
Issuance of stock, shares		198,280
Unrealized gain on available-for-sale securities	1			$ 1
Net loss	(4,138)				(4,138)
Balance at Mar. 31, 2017	$ 13,836	$ 2	$ 165,954		$ (152,120)
Balance (in shares) at Mar. 31, 2017		1,000,036

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Activities
Net loss	$ (4,138,000)	$ (3,592,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	120,000	153,000
Depreciation and amortization	48,000	105,000
Gain on extinguishment of redeemable convertible notes	0	(85,000)
Change in fair value of derivative liability		(875,000)
Changes in operating assets and liabilities:
Accounts receivable	(196,000)	44,000
Prepaid and other current assets	(83,000)	281,000
Accounts payable	62,000	(222,000)
Accrued compensation and other accrued liabilities	(26,000)	(441,000)
Deferred rent	(8,000)	(3,000)
Deferred revenue	(71,000)	(109,000)
Net cash flows used in operating activities	(4,292,000)	(4,744,000)
Investing Activities
Proceeds from maturities of short-term investments	6,801,000
Purchase of investments		(3,682,000)
Change in restricted cash	(19,000)	(1,000)
Purchases of property and equipment	(3,000)	(89,000)
Net cash flows (used in) provided by investing activities	6,779,000	(3,772,000)
Financing Activities
Release of restricted cash due to conversion and redemption of redeemable convertible notes	6,752,000	2,807,000
Payments for the redemption of redeemable convertible notes	(6,752,000)	(2,807,000)
Proceeds from issuance of common stock, net of issuance costs	1,782,000
Net cash flows provided by financing activities	1,782,000
Net (decrease) increase in cash and cash equivalents	4,269,000	(8,516,000)
Cash and cash equivalents at beginning of period	10,264,000	29,096,000
Cash and equivalents at end of period	14,533,000	20,580,000
Supplemental Disclosure of Non-Cash Investing and Financing Information:
Unrealized Gain (Loss) on investments	$ 1,000	$ 3,000

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	1. Catalyst Biosciences, Inc. (the “Company” or “Catalyst”), is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment. Prior to August 20, 2015, the name of the Company was Targacept, Inc. (“Targacept”). On August 20, 2015, Targacept completed its business combination with Catalyst Bio, Inc. (“Catalyst Bio”) by and among Targacept, Talos Merger Sub, Inc. (“Merger Sub”) and Catalyst Bio, pursuant to which Merger Sub merged with and into Catalyst Bio, with Catalyst Bio surviving as a wholly-owned subsidiary of Targacept (the “Merger”) and changed its name from Targacept, Inc. to Catalyst Biosciences, Inc. Prior to and in connection with the Merger, the Company paid a dividend to the Targacept holders consisting of cash and non-interest bearing redeemable convertible notes (the “Pre-Closing Dividend”), see Note 5 On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (“2017 Reverse Stock Split”). The 2017 Reverse Stock Split was approved by the Company’s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares. Unless otherwise specified, all share and per share amounts in these notes and the accompanying consolidated financial statements are reported on a post-stock split basis for all periods presented. On April 3, 2017, under the Company’s at the market offering program with JonesTrading Institutional Services LLC (“JonesTrading”), the Company sold an aggregate of 241,600 shares of its common stock for approximately $3.5 million of net proceeds. Following such sales, the Company has no more common stock available for sale under the program. On April 12, 2017, the Company issued and sold in a registered, underwritten public offering an aggregate of (i) 1,470,000 shares of common stock (including 540,000 shares of common stock sold pursuant to the exercise of the Underwriter’s overallotment option), (ii) 13,350 shares of Series A Preferred Stock, each convertible into 200 shares of common stock and (iii) warrants to purchase 2,070,000 shares of common stock at an exercise price of $5.50 per share (including 270,000 sold pursuant to the exercise of the underwriter’s overallotment option). The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company was approximately $18.7 million.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). The Company’s significant accounting policies are included in “ Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. For a description of the fair value hierarchy and the Company’s fair value methodology, see “ Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies Liabilities that are measured at fair value consist of the derivative liability and is valued using Level 3 inputs. There were no transfers in or out of Level 3 during the periods presented. As of March 31, 2017 and December 31, 2016 the fair value of the derivative liability was immaterial. The estimated reporting date fair value-based measurement of the derivative liability was calculated using the Black-Scholes valuation model. The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 ( in thousands March 31, 2017 Level 1 Level 2 Level 3 Total Financial assets: Money market funds (1) $ 14,619 — — $ 14,619 Restricted cash (money market funds) (2) 12,860 — — 12,860 Total financial assets $ 27,479 $ — $ — $ 27,479 (1) Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets. (2) $12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease. December 31, 2016 Level 1 Level 2 Level 3 Total Financial assets: Money market funds (1) $ 10,156 $ — $ — $ 10,156 Restricted cash (money market funds) (2) 19,593 — — 19,593 U.S. government agency securities (3) 6,800 — — 6,800 Total financial assets $ 36,549 $ — $ — $ 36,549 (1) Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets. (2) $19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease. (3) Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2017
Investments All Other Investments [Abstract]
Financial Instruments	4. Cash equivalents, restricted cash and short-term investments, all of which are classified as available-for-sale securities, consisted of the following ( in thousands March 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Money market funds $ 14,619 $ — $ — $ 14,619 Restricted cash (money market funds) 12,860 — — 12,860 Total financial assets $ 27,479 $ — $ — $ 27,479 Classified as: Cash and cash equivalents $ 14,619 Restricted cash (money market funds) 12,860 $ 27,479 December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Money market funds $ 10,156 $ — $ — $ 10,156 Restricted cash (money market funds) 19,593 — — 19,593 Corporate notes 6,802 — (2 ) 6,800 Total financial assets $ 36,551 $ — $ (2 ) $ 36,549 Classified as: Cash and cash equivalents $ 10,156 Restricted cash (money market funds) 19,593 Short-term investments 6,800 $ 36,549 There have been no significant realized gains or losses on available-for-sale securities for the periods presented. The carrying amounts of cash, accounts receivable and accounts payable approximate fair values due to the short-term maturity of these instruments.

Redeemable Convertible Notes

Redeemable Convertible Notes	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Redeemable Convertible Notes	5. On August 19, 2015, immediately prior to the Merger, the Company issued to Targacept stockholders non-interest bearing redeemable convertible notes (the “Notes”) in the aggregate principal amount of $37.0 million. The Notes do not bear interest. The principal amount of the Notes are convertible, at the option of each noteholder, into cash or into shares of the Company’s common stock at a conversion rate of $137.85 per share, and are payable in cash, if not previously redeemed or converted, at maturity on February 19, 2018, the 30-month anniversary of the closing of the issuance of the Notes. In connection with the Pre-Closing Dividend, on August 19, 2015, Targacept entered into an indenture (the “Indenture”) with American Stock Transfer & Trust Company, LLC, as trustee, and an escrow agreement with American Stock Transfer & Trust Company, LLC and Delaware Trust Company, LLC, as escrow agent, under which $37.0 million, which represented the initial principal amount of the convertible notes, was deposited in a segregated escrow account for the benefit of the holders of the notes in order to facilitate the payment of the notes upon redemption or at maturity (the amount of such deposit together with interest accrued and capitalized thereon, the “Escrow Funds”). The Notes are the Company’s secured obligation, and the Indenture does not limit its other indebtedness, secured or unsecured. Holders of the Notes may submit conversion notices, which are irrevocable, instructing the trustee to convert such Notes into shares of common stock at a conversion price of $137.85 per share. Following each conversion date, the Company will issue the number of whole shares of common stock issuable upon conversion as promptly as practicable (and in any event within 10 business days). The trustee will in turn release to the Company the respective amount of restricted cash to cover the stock issuance. The conversion to common stock feature of the Notes was determined to be a derivative liability requiring bifurcation and separate accounting. The fair value of such conversion feature at issuance was determined to be $1.5 million. The bifurcation of the derivative liability from the estimated fair value of the Notes of $37.1 million at issuance resulted in a debt discount of $1.4 million. The Company elected to accrete the entire debt discount as interest expense immediately after the Merger. In addition, changes in the fair value of the derivative liability are being recorded within interest and other income in the consolidated statements of operations. The Company remeasures the derivative liability to fair value until the earlier of the conversion, redemption or maturity of the redeemable convertible notes. As of March 31, 2017 and December 31, 2016, the fair value of the derivative liability was immaterial. The estimated reporting date fair value-based measurement of the derivative liability was calculated using the Black-Scholes valuation model. The Company recognized no interest expense for both the three months ended March 31, 2017 and 2016, related to the amortization of the debt discount within interest expense on the Company’s consolidated statement of operations as the redeemable convertible notes are immediately fully redeemable at the option of the holders. As of March 31, 2017, $24.1 million of the Notes were redeemed and $0.3 million of the Notes were converted into common stock. $6.7 million of the Notes were redeemed during the three months ended March 31, 2017. The Company recognized no gain on the extinguishment of Notes upon the redemption of the Notes during the three months ended March 31, 2017.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	6. The following table summarizes stock option activity under the Company’s equity incentive plans, including stock options granted to non-employees, and related information: Number of Shares Underlying Outstanding Options Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Outstanding — December 31, 2016 140,990 $ 127.56 3.93 Options granted — Options forfeited (15,495 ) $ 188.73 Outstanding — March 31, 2017 125,495 $ 120.00 4.13 Exercisable — March 31, 2017 93,959 $ 143.44 2.58 Vested and expected to vest — March 31, 2017 125,495 $ 120.00 4.13 Valuation Assumptions The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. The fair value of employee stock options was estimated using the following weighted-average assumptions for the three months ended March 31, 2016: Three Months Ended March 31, 2016 Employee Stock Options: Risk-free interest rate 1.57 % Expected term (in years) 6.04 Dividend yield — Volatility 73.28 % Weighted-average fair value of stock options granted $ 21.15 Total stock-based compensation recognized was as follows ( in thousands Three Months Ended March 31, 2017 2016 Research and development $ 20 $ 50 General and administrative 100 103 Total stock-based compensation $ 120 $ 153 As of March 31, 2017, 101,304 shares of common stock were available for future grant, 44,704 options to purchase shares of common stock were outstanding and the Company had unrecognized employee stock-based compensation expense of $1.0 million, related to unvested stock awards, which is expected to be recognized over an estimated weighted-average period of 2.36 years.

Collaborations

Collaborations	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations	7. Pfizer On August 20, 2013, the Company and Pfizer signed an amendment to the Factor VIIa collaboration agreement in which the companies agreed to provide specific mutual releases and covenants and modify certain milestone payment schedules in the agreement. On April 2, 2015, Pfizer notified the Company that it was exercising its right to terminate the research and license agreement effective June 1, 2015. The termination became effective 60 days after the Company’s receipt of the termination notice. On June 1, 2015, the license and certain rights under the research and license agreement terminated and reverted to the Company. On December 8, 2016, the Company signed an agreement with Pfizer pursuant to which the parties terminated the research and license agreement that was signed on June 29, 2009. Pursuant to the new agreement, Pfizer granted the Company an exclusive license to Pfizer’s proprietary rights for manufacturing and processes that apply to Factor VIIa variants, CB 813a (marzeptacog alfa (activated)). Pfizer has also transferred and will transfer to the Company documentation related to the development, manufacturing and testing of the Products, including the Investigational New Drug (“IND”) application as well as the orphan drug designation. As part of the new agreement, the Company agreed to make contingent cash payments to Pfizer in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any covered product, Pfizer would also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. No amounts have been paid to date under this new agreement. ISU Abxis On June 16, 2013, the Company signed a license and collaboration agreement with ISU Abxis, whereby the Company licensed its proprietary human Factor IX products to ISU Abxis for initial development in South Korea. Under the terms of the agreement, ISU Abxis is responsible for manufacturing, preclinical development activities and clinical development through completion of a proof-of-concept Phase 1/2 study in individuals with hemophilia B. The Company has the sole rights and responsibility for worldwide development, manufacture, and commercialization of Factor IX products after Phase 1/2 development. ISU Abxis may exercise its right of first refusal to acquire commercialization rights in South Korea, in which case they would be entitled to profit sharing on worldwide sales. ISU’s rights will also terminate if the Company enters into a license agreement with another party to develop, manufacture and commercialize Factor IX products in at least two major market territories. ISU Abxis paid the Company an up-front signing fee of $1.75 million and is obligated to pay to the Company contingent milestone-based payments on the occurrence of certain defined development events, and reimbursement for a portion of the Company’s costs relating to intellectual property filings and maintenance thereof on products. The Company is obligated to pay ISU Abxis a percentage of all net profits it receives from collaboration products. Contract revenue of $0.3 million and $0.1 million for the three months ended March 31, 2017 and 2016, respectively, reflected (i) the amortization of the up-front fee over the estimated period of the Company’s performance obligations under the agreement, which was assessed to be four years beginning in September 2013 when the agreement was executed and (ii) $0.2 million recorded in March 2017 for a milestone payment earned by the Company. The deferred revenue balance related to the ISU Abxis collaboration was $0.3 million and $0.6 million as of March 31, 2017 and 2016, respectively.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss per Share	8. The following table sets forth the computation of the basic and diluted net loss per share during the three months ended March 31, 2017 and 2016 ( in thousands, except share and per share data Three Months Ended March 31, 2017 2016 Net loss, basic and diluted $ (4,138 ) $ (3,592 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 906,048 762,007 Net loss per share, basic and diluted $ (4.57 ) $ (4.71 ) Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities on an as-if converted basis that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: March 31, December 31, 2017 2016 Options to purchase common stock 125,495 140,990 Common stock warrants 12,039 12,063 Redeemable convertible notes 92,462 140,743 Total 229,996 293,796

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Common Stock	9. Common Stock On March 16, 2016, the Company signed a Capital on Demand TM The Company sold 198,280 shares of common stock in the open market at a weighted-average selling price of $9.55 per share, for net proceeds (net of commissions) of $1.8 million during the three months ended March 31, 2017, in the Capital on Demand TM

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Operating Leases The Company leases office space for its corporate headquarters in South San Francisco, California. The lease will expire in February 2018. Future minimum lease payments under all non-cancelable operating leases as of March 31, 2017, were as follows ( in thousands Minimum Lease Payments 2017 561 2018 125 Total future minimum lease payments 686 Manufacturing Agreements On May 20, 2016, the Company entered into a development and manufacturing services agreement with CMC ICOS Biologics, Inc. (“CMC”), pursuant to which CMC will conduct manufacturing development and, upon successful development of the manufacturing process, manufacture the Company’s next-generation Factor VIIa variant marzeptacog alfa (activated) that the Company intends to use in its clinical trials. The Company has agreed to a total of $3.8 million in payments to CMC pursuant to the initial statement of work under the Agreement, subject to completion of applicable work stages. As of March 31, 2017, the Company was obligated to $2.1 million in payments to CMC remaining under the agreement.

Interest and Other Income

Interest and Other Income	3 Months Ended
	Mar. 31, 2017
Other Income And Expenses [Abstract]
Interest and Other Income	11. Interest and Other Income As of March 31, 2017 and December 31, 2016, the fair value of the derivative liability was immaterial. The following table shows the detail of other income/(expense), net for the three month periods ended March 31, 2017 and 2016 ( in thousands Three Months Ended March 31, 2017 2016 Change in derivative liability $ — $ 960 Other Income, net 33 20 Total Other Income/(expense), net $ 33 $ 980

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent events On April 3, 2017, under the Company’s at the market offering program with JonesTrading, the Company sold an aggregate of 241,600 shares of its common stock for approximately $3.5 million of net proceeds. Following such sales, the Company has no more common stock available for sale under the program. On April 12, 2017, the Company issued and sold in a registered, underwritten public offering an aggregate of (i) 1,470,000 shares of common stock (including 540,000 shares of common stock sold pursuant to the exercise of the Underwriter’s overallotment option), (ii) 13,350 shares of Series A Preferred Stock, each convertible into 200 shares of common stock and (iii) warrants to purchase 2,070,000 shares of common stock at an exercise price of $5.50 per share (including 270,000 sold pursuant to the exercise of the Underwriter’s overallotment option). The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company was approximately $18.7 million. In connection with and following the Company’s underwritten public offering, certain holders of Series A Preferred Stock and warrants elected to convert or exercise such shares and warrants, respectively. In addition, subsequent to March 31, 2017, additional redeemable convertible notes were redeemed by the holders thereof. Accordingly, as of May 4, 2017, the Company had outstanding 4,260,561 shares of common stock, 5,750 shares of Series A Preferred Stock (convertible into an aggregate of 1,150,000 shares of common stock), warrants to purchase 2,041,075 shares of common stock at an exercise price of $5.50 per share, and options under the Company’s 2015 Stock Incentive Plan to purchase an aggregate of 44,670 shares of common stock at a weighted-average exercise price of $58.65 per share (in addition to other warrants to purchase an aggregate of 12,039 shares of common stock at a weighted-average exercise price of $145.11 per share, other options to purchase an aggregate of 80,619 shares of common stock at a weighted-average exercise price of $154.01 per share and $11.0 million of redeemable convertible promissory notes convertible at a rate of $137.85 per share).

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). The Company’s significant accounting policies are included in “ Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 ( in thousands March 31, 2017 Level 1 Level 2 Level 3 Total Financial assets: Money market funds (1) $ 14,619 — — $ 14,619 Restricted cash (money market funds) (2) 12,860 — — 12,860 Total financial assets $ 27,479 $ — $ — $ 27,479 (1) Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets. (2) $12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease. December 31, 2016 Level 1 Level 2 Level 3 Total Financial assets: Money market funds (1) $ 10,156 $ — $ — $ 10,156 Restricted cash (money market funds) (2) 19,593 — — 19,593 U.S. government agency securities (3) 6,800 — — 6,800 Total financial assets $ 36,549 $ — $ — $ 36,549 (1) Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets. (2) $19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease. (3) Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Investments All Other Investments [Abstract]
Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities	Cash equivalents, restricted cash and short-term investments, all of which are classified as available-for-sale securities, consisted of the following ( in thousands March 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Money market funds $ 14,619 $ — $ — $ 14,619 Restricted cash (money market funds) 12,860 — — 12,860 Total financial assets $ 27,479 $ — $ — $ 27,479 Classified as: Cash and cash equivalents $ 14,619 Restricted cash (money market funds) 12,860 $ 27,479 December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Money market funds $ 10,156 $ — $ — $ 10,156 Restricted cash (money market funds) 19,593 — — 19,593 Corporate notes 6,802 — (2 ) 6,800 Total financial assets $ 36,551 $ — $ (2 ) $ 36,549 Classified as: Cash and cash equivalents $ 10,156 Restricted cash (money market funds) 19,593 Short-term investments 6,800 $ 36,549

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Option Activity under Company's Equity Incentive Plans	The following table summarizes stock option activity under the Company’s equity incentive plans, including stock options granted to non-employees, and related information: Number of Shares Underlying Outstanding Options Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Outstanding — December 31, 2016 140,990 $ 127.56 3.93 Options granted — Options forfeited (15,495 ) $ 188.73 Outstanding — March 31, 2017 125,495 $ 120.00 4.13 Exercisable — March 31, 2017 93,959 $ 143.44 2.58 Vested and expected to vest — March 31, 2017 125,495 $ 120.00 4.13
Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options	The fair value of employee stock options was estimated using the following weighted-average assumptions for the three months ended March 31, 2016: Three Months Ended March 31, 2016 Employee Stock Options: Risk-free interest rate 1.57 % Expected term (in years) 6.04 Dividend yield — Volatility 73.28 % Weighted-average fair value of stock options granted $ 21.15
Summary of Stock-Based Compensation Recognized	Total stock-based compensation recognized was as follows ( in thousands Three Months Ended March 31, 2017 2016 Research and development $ 20 $ 50 General and administrative 100 103 Total stock-based compensation $ 120 $ 153

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the basic and diluted net loss per share during the three months ended March 31, 2017 and 2016 ( in thousands, except share and per share data Three Months Ended March 31, 2017 2016 Net loss, basic and diluted $ (4,138 ) $ (3,592 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 906,048 762,007 Net loss per share, basic and diluted $ (4.57 ) $ (4.71 )
Anti-dilutive Security not Included In Diluted per Share Calculations	Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities on an as-if converted basis that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: March 31, December 31, 2017 2016 Options to purchase common stock 125,495 140,990 Common stock warrants 12,039 12,063 Redeemable convertible notes 92,462 140,743 Total 229,996 293,796

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Expected Future Lease Payments Under All Operating Leases	Future minimum lease payments under all non-cancelable operating leases as of March 31, 2017, were as follows ( in thousands Minimum Lease Payments 2017 561 2018 125 Total future minimum lease payments 686

Other Income (Expense) (Tables)

Other Income (Expense) (Tables)	3 Months Ended
	Mar. 31, 2017
Other Income And Expenses [Abstract]
Detail of Other Income/(Expense), Net	The following table shows the detail of other income/(expense), net for the three month periods ended March 31, 2017 and 2016 ( in thousands Three Months Ended March 31, 2017 2016 Change in derivative liability $ — $ 960 Other Income, net 33 20 Total Other Income/(expense), net $ 33 $ 980

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail)	Apr. 12, 2017USD ($)$ / sharesshares	Apr. 03, 2017USD ($)shares	Feb. 10, 2017shares	Mar. 31, 2017USD ($)shares	Feb. 02, 2017shares	Dec. 31, 2016shares
Organization and Nature of Operations [Line Items]
Common stock, shares outstanding				1,000,036		801,756
Proceeds from issuance of common stock, net of issuance costs | $				$ 1,782,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Organization and Nature of Operations [Line Items]
Issuance of stock, shares				198,280
Proceeds from issuance of common stock, net of issuance costs | $				$ 1,800,000
Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares				198,280
Subsequent Event
Organization and Nature of Operations [Line Items]
Proceeds from issuance of common stock, net of issuance costs | $	$ 18,700,000
Warrants exercise shares	2,070,000
Warrants exercise price | $ / shares	$ 5.50
Subsequent Event | Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Organization and Nature of Operations [Line Items]
Issuance of stock, shares		241,600
Proceeds from issuance of common stock, net of issuance costs | $		$ 3,500,000
Common stock available for sale | $		$ 0
Subsequent Event | Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	1,470,000
Subsequent Event | Series A Preferred Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	13,350
Conversion of redeemable convertible notes to common stock	200
Overallotment Option | Subsequent Event
Organization and Nature of Operations [Line Items]
Warrants exercise shares	270,000
Overallotment Option | Subsequent Event | Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	540,000
2017 Reverse Stock Split
Organization and Nature of Operations [Line Items]
Reverse stock split, description				On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (“2017 Reverse Stock Split”). The 2017 Reverse Stock Split was approved by the Company’s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares.
Reverse stock split ratio			0.06667
Common stock, shares outstanding			868,000		13,000,000

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value (Detail) - USD ($) $ in Thousands		Mar. 31, 2017		Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value		$ 27,479		$ 36,549
Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	[1]	14,619		10,156
Restricted cash (money market funds)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value		12,860	[2]	19,593	[3]
U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	[4]			6,800
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value		27,479		36,549
Fair Value, Inputs, Level 1 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	[1]	14,619		10,156
Fair Value, Inputs, Level 1 | Restricted cash (money market funds)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value		$ 12,860	[2]	19,593	[3]
Fair Value, Inputs, Level 1 | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	[4]			$ 6,800
[1]	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.
[2]	$12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.
[3]	$19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.
[4]	Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

Assets and Liabilities Measur29

Assets and Liabilities Measured at Fair Value (Parenthetical) (Detail) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 12,735,000	$ 19,468,000
Collateral for Redeemable Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	12,700,000	19,400,000
Collateral for Corporate Credit Card and Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 125,000	$ 125,000

Cash Equivalents, Restricted Ca

Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 27,479	$ 36,551
Gross Unrealized Losses		(2)
Estimated Fair Value	27,479	36,549
Money Market Funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,619	10,156
Estimated Fair Value	14,619	10,156
Money Market Funds | Restricted cash (money market funds)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,860	19,593
Estimated Fair Value	12,860	19,593
Corporate Notes
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		6,802
Gross Unrealized Losses		(2)
Estimated Fair Value		6,800
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	$ 14,619	10,156
Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value		$ 6,800

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value Disclosures [Abstract]
Significant realized gains or losses on available-for-sale securities	$ 0

Redeemable Convertible Notes -

Redeemable Convertible Notes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Aug. 19, 2015
Debt Instrument [Line Items]
Gain on extinguishment of redeemable convertible notes	$ 0	$ 85,000
Redeemable convertible notes, redeemed during period	$ 6,752,000	2,807,000
Convertible Notes
Debt Instrument [Line Items]
Convertible notes, total outstanding principal amount			$ 37,000,000
Redeemable convertible notes, conversion per share price	$ 137.85
Convertible notes, maturity date	Feb. 19, 2018
Convertible notes, maturity period	30 months
Redeemable convertible notes, threshold trading days	10 days
Redeemable convertible notes, conversion feature	$ 1,500,000
Redeemable convertible notes, estimated fair value	37,100,000
Redeemable convertible notes, debt discount	1,400,000
Redeemable convertible notes, interest expense	0	$ 0
Redeemable convertible notes, redeemed	24,100,000
Conversion of convertible notes in to common stock, value	300,000
Redeemable convertible notes, redeemed during period	$ 6,700,000
Convertible Notes | After Reverse Stock Split
Debt Instrument [Line Items]
Redeemable convertible notes, conversion per share price	$ 137.85

Summary of Option Activity unde

Summary of Option Activity under Company's Equity Incentive Plans (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of Shares Underlying Outstanding Options
Number of Shares Underlying Outstanding Options, Beginning Balance	140,990
Number of Shares Underlying Outstanding Options, Options forfeited	(15,495)
Number of Shares Underlying Outstanding Options, Ending Balance	125,495	140,990
Number of Shares Underlying Outstanding Options, Exercisable — March 31, 2017	93,959
Number of Shares Underlying Outstanding Options, Vested and expected to vest — March 31, 2017	125,495
Weighted- Average Exercise Price
Weighted- Average Exercise Price, Beginning Balance	$ 127.56
Weighted- Average Exercise Price, Options forfeited	188.73
Weighted- Average Exercise Price, Ending Balance	120	$ 127.56
Weighted- Average Exercise Price, Exercisable — March 31, 2017	143.44
Weighted- Average Exercise Price, Vested and expected to vest — March 31, 2017	$ 120
Weighted-Average Remaining Contractual Term (Years)
Weighted-Average Remaining Contractual Term (Years), Outstanding Balance	4 years 1 month 17 days	3 years 11 months 5 days
Weighted-Average Remaining Contractual Term (Years), Exercisable — March 31, 2017	2 years 6 months 29 days
Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest — March 31, 2017	4 years 1 month 17 days

Fair Values of Stock Options Es

Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail) - Employee Stock Option	3 Months Ended
	Mar. 31, 2016$ / shares
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]
Risk-free interest rate	1.57%
Expected term (in years)	6 years 15 days
Dividend yield	0.00%
Volatility	73.28%
Weighted-average fair value of stock options granted	$ 21.15

Summary of Stock-Based Compensa

Summary of Stock-Based Compensation Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 120	$ 153
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	20	50
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 100	$ 103

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock available for future grant	101,304
Shares remaining outstanding	44,704
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized employee stock based compensation expense | $	$ 1
Unrecognized employee stock based compensation expense, period for recognition	2 years 4 months 10 days

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($)	Apr. 02, 2015	Jun. 16, 2013	Mar. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 08, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract revenue				$ 271,000	$ 109,000
Pfizer Inc
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Effective termination notice period	60 days
Pfizer Inc | Collaboration Agreement | Maximum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contingent cash payments upon achievement of clinical, regulatory and commercial milestones						$ 17,500,000
ISU Abxis
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract revenue				300,000	100,000
Deferred revenue			$ 300,000	$ 300,000	$ 600,000
Deferred revenue recognition period				4 years
Milestone payment received			$ 200,000
ISU Abxis | Up Front Payment
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Amount received for research and development process		$ 1,750,000

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Net loss, basic and diluted	$ (4,138)	$ (3,592)
Weighted-average number of shares used in computing net loss per share, basic and diluted	906,048	762,007
Net loss per share, basic and diluted	$ (4.57)	$ (4.71)

Anti-dilutive Security not Incl

Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	229,996	293,796
Options To Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	125,495	140,990
Common Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	12,039	12,063
Redeemable Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	92,462	140,743

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 16, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, value of shares issued under sales agreement	$ 2,000	$ 1,000
Net proceeds from sale of common stock	$ 1,782,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued under sales agreement	198,280
Common stock weighted average selling price	$ 9.55
Net proceeds from sale of common stock	$ 1,800,000
Commission against additional paid-in capital	$ 100,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, value of shares issued under sales agreement			$ 6,500,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	May 20, 2016
Commitments And Contingencies Disclosure [Line Items]
Operating lease expiration date	2018-02
CMC ICOS Biologics, Inc.
Commitments And Contingencies Disclosure [Line Items]
Contractual obligation payments	$ 2.1	$ 3.8

Expected Future Lease Payments

Expected Future Lease Payments Under Operating Leases (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 561
2,018	125
Total future minimum lease payments	$ 686

Detail of Other Income_(Expense

Detail of Other Income/(Expense), Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Other Income And Expenses [Abstract]
Change in derivative liability		$ 960
Other Income, net	$ 33	20
Total Other Income/(expense), net	$ 33	$ 980

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May 04, 2017	Apr. 12, 2017	Apr. 03, 2017	Mar. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 1,782
Common stock, shares outstanding				1,000,036	801,756
Preferred stock, shares outstanding				0	0
Options to purchase aggregate shares of common stock				93,959
Options to purchase aggregate shares of common stock, weighted-average exercise price				$ 120	$ 127.56
Options to purchase aggregate shares of common stock, weighted-average exercise price				143.44
Redeemable Convertible Promissory Notes
Subsequent Event [Line Items]
Redeemable convertible notes, conversion per share price				$ 137.85
Common Stock
Subsequent Event [Line Items]
Issuance of stock, shares				198,280
Subsequent Event
Subsequent Event [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 18,700
Warrants to purchase common stock		2,070,000
Warrants exercise price		$ 5.50
Subsequent Event | Overallotment Option
Subsequent Event [Line Items]
Warrants to purchase common stock		270,000
Subsequent Event | Public Offering
Subsequent Event [Line Items]
Warrants exercise price	$ 5.50
Common stock, shares outstanding	4,260,561
Subsequent Event | Public Offering | 2015 Stock Incentive Plan
Subsequent Event [Line Items]
Options to purchase aggregate shares of common stock	44,670
Subsequent Event | Public Offering | Other Warrants to Purchase Common Stock
Subsequent Event [Line Items]
Warrants exercise price	$ 145.11
Subsequent Event | Public Offering | Other Options to Purchase Common Stock
Subsequent Event [Line Items]
Warrants to purchase common stock	12,039
Subsequent Event | Public Offering | Other Options to Purchase Common Stock | 2015 Stock Incentive Plan
Subsequent Event [Line Items]
Options to purchase aggregate shares of common stock	80,619
Options to purchase aggregate shares of common stock, weighted-average exercise price	$ 58.65
Options to purchase aggregate shares of common stock, weighted-average exercise price	$ 154.01
Subsequent Event | Public Offering | Redeemable Convertible Promissory Notes
Subsequent Event [Line Items]
Redeemable convertible promissory notes convertible into share	$ 11,000
Redeemable convertible notes, conversion per share price	$ 137.85
Subsequent Event | Series A Preferred Stock
Subsequent Event [Line Items]
Issuance of stock, shares		13,350
Conversion of redeemable convertible notes to common stock		200
Subsequent Event | Series A Preferred Stock | Public Offering
Subsequent Event [Line Items]
Preferred stock, shares outstanding	5,750
Subsequent Event | Common Stock
Subsequent Event [Line Items]
Issuance of stock, shares		1,470,000
Subsequent Event | Common Stock | Overallotment Option
Subsequent Event [Line Items]
Issuance of stock, shares		540,000
Subsequent Event | Common Stock | Public Offering
Subsequent Event [Line Items]
Warrants to purchase common stock	2,041,075
Subsequent Event | Common Stock | Series A Preferred Stock | Public Offering
Subsequent Event [Line Items]
Conversion of redeemable convertible notes to common stock	1,150,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Subsequent Event [Line Items]
Issuance of stock, shares				198,280
Proceeds from issuance of common stock, net of issuance costs				$ 1,800
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC | Subsequent Event
Subsequent Event [Line Items]
Issuance of stock, shares			241,600
Proceeds from issuance of common stock, net of issuance costs			$ 3,500